LevitasBio is a Menlo Park, Calif.-based provider of end-to-end sample processing and analysis to the life sciences market. Its core technology is a proprietary label-free levitation platform designed to preserve biological signatures without altering, stressing, or damaging cells. The company offers products including LeviPrep cold tissue dissociation kits, LeviSelect surface marker enrichment assays, the LeviCell EOS high-throughput sample processing platform with temperature control, and LeviMetrics integrated analysis software. LevitasBio says its solutions deliver higher quality and quantity of viable, unaltered cells for clearer downstream data and analysis. With a completed $35 million Series C, the company plans to accelerate commercial success and develop next-generation high-throughput instruments for sample processing and analysis. Existing life sciences and pharmaceutical development clients have validated the technology and company leadership aims to position LevitasBio as a benchmark platform for sample processing workflows.

Total raised

$35M

Funding rounds

1

Latest round

Series C

Latest activity

Nov 2022